Findings support PSMA PET in the preoperative workflow of intermediate- and high-risk tumors
What’s New
- High Decipher Score is Predictive of Docetaxel Benefit in Advanced Prostate Cancer
- FDA Approves First PSMA-Targeted Therapy for Metastatic Castration-Resistant Prostate Cancer
- Survival, Progression Improves With Xofigo Plus Xtandi for Certain Patients With Prostate Cancer
- Why Some Men Keep Their Prostate Cancer a Secret
- PSMA-PET by PROMISE Criteria Shows Prognostic Value Across Prostate Cancer Continuum